Patents by Inventor Douglas Linn Gernert

Douglas Linn Gernert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AHR AGONISTS
    Publication number: 20230159493
    Abstract: The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: May 25, 2023
    Inventors: Lacie Marie CHAUVIGNE-HINES, Christian Alexander CLARKE, Douglas Linn GERNERT, Steven James GREEN, Brian Morgan WATSON
  • SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES
    Publication number: 20230136885
    Abstract: The present invention provides a compound of Formula (I) wherein R is (II) or (III), or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 4, 2023
    Inventors: Thomas John BLEISCH, Douglas Linn GERNERT, Freddie Craig STEVENS
  • AHR AGONISTS
    Publication number: 20230127797
    Abstract: The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 27, 2023
    Inventors: Cheryl Ann CARSON, Christian Alexander CLARKE, Douglas Linn GERNERT, Steven James GREEN, William Glen HOLLOWAY
  • 6-substituted-3-1,3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists
    Patent number: 9469632
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Kevin Matthew Gardinier, Douglas Linn Gernert, Patric James Hahn, Sean Patrick Hollinshead, Albert Khilevich, Daniel Ray Mayhugh, Paul Leslie Ornstein, Warren Jaye Porter, Jon Kevin Reel, Jeffrey Michael Schkeryantz, Patrick Gianpietro Spinazze, Freddie Craig Stevens, Jeffrey Michael Witkin
  • 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS
    Publication number: 20150344468
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Application
    Filed: May 21, 2015
    Publication date: December 3, 2015
    Inventors: Kevin Matthew GARDINIER, Douglas Linn GERNERT, Patric James HAHN, Sean Patrick HOLLINSHEAD, Albert KHILEVICH, Daniel Ray MAYHUGH, Paul Leslie ORNSTEIN, Warren Jaye PORTER, Jon Kevin REEL, Jeffrey Michael SCHKERYANTZ, Patrick Gianpietro SPINAZZE, Freddie Craig STEVENS, Jeffrey Michael WITKIN
  • Compounds and methods for treating dislipidemia
    Patent number: 7749992
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Triazole PPAR modulators
    Patent number: 7507832
    Abstract: The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: March 24, 2009
    Assignee: Eli Lilly and Company
    Inventors: Nathan Bryan Mantlo, Antonio Navarro, Ashraf Saeed, Douglas Linn Gernert, Tianwei Ma, Lance Allen Pfeifer